REFERENCES
- Greenfield DS, Liebmann JM, Ritch R. Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment. J Glaucoma. 1997;6:250–258
- Schuman JS, Horwitz B, Choplin NT, et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol. 1997;115:847–852
- Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group. Am J Ophthalmol. 1999;127:20–26
- LeBlanc RP. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. Ophthalmology. 1998;105:1960–1967
- Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol. 1996;41 Suppl 1:S27–S37
- Mundorf T, Wilcox KA, Ousler GW 3rd, et al. Evaluation of the comfort of Alphagan P compared with Alphagan in irritated eyes. Adv Ther. 2003;20:329–336
- Byles DB, Frith P, Salmon JF. Anterior uveitis as a side effect of topical brimonidine. Am J Ophthalmol. 2000;130:287–291
- Goyal R, Ram AR. Brimonidine tartrate 0.2% (Alphagan) associated granulomatous anterior uveitis. Eye (Lond). 2000;14:908–910
- Cates CA, Jeffrey MN. Granulomatous anterior uveitis associated with 0.2% topical brimonidine. Eye (Lond). 2003;17:670–671
- Becker HI, Walton RC, Diamant JI, et al. Anterior uveitis and concurrent allergic conjunctivitis associated with long-term use of topical 0.2% brimonidine tartrate. Arch Ophthalmol. 2004;122:1063–1066
- Velasque L, Ducousso F, Pernod L, et al. Anterior uveitis and topical brimonidine: a case report. J Fr Ophtalmol. 2004;27:1150–1152
- Nguyen EV, Azar D, Papalkar D, et al. Brimonidine induced anterior uveitis and conjunctivitis: clinical and histologic features. J Glaucoma. 2008;17:40–42
- Hondeghem K, Augustinus B, De Smet MD. Bilateral granulomatous uveitis as a side effect of topical brimonidine: two case reports. Bull Soc Belge Ophtalmol. 2009;311:51–52
- Miller RY, Anthony S. Suspected brimonidine allergy associated with severe bilateral conjunctivitis and anterior granulomatous uveitis. Optometry. 2009;80:299
- Casado A, Cabarga C, de la Fuente MA and Munoz-Negrete FJ. Suspected granulomatous anterior uveitis associated with brimonidine tartrate 0.2% and timolol maleate 0.5% ophthalmic solution. Graefes Arch Clin Exp Ophthalmol. 2013;251:2659–2660
- Carrasco MA, Schlaen BA, Za’rate JO. Brimonidine–timolol fixed combination induced granulomatous inflammation of the eye. Int Ophthalmol. 2013;33:557–560
- McKnight CM, Richards JC, Daniels D, Morgan WH. Brimonidine (Alphagan) associated anterior uveitis. Br J Ophthalmol. 2012;96:766–768
- Fraunfelder FW, Rosenbaum JT. Drug-induced uveitis. Incidence, prevention and treatment. Drug Saf. 1997;17:197–207
- Akingbehin T, Villada JR. Metipranolol-associated granulomatous anterior uveitis. Br J Ophthalmol. 1991;75:519–523
- Akingbehin T, Villada JR, Walley T. Metipranolol-induced adverse reactions: I. The rechallenge study. Eye. 1992;6:277–279
- Krupin T, Leblanc RP, Becker B, et al. Uveitis in association with topically administered corticosteroid. Am J Ophthalmol. 1970;70:883–885
- Fraunfelder FT. Drug induced ocular side effects and drug interactions. Philadelphia: Lea and Febiger; 1989:617–618
- Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology. 1998;105:263–268
- O’Connor GR. Granulomatous uveitis and metipranolol. Br J Ophthalmol. 1993;77:536–537